0000000001157963

AUTHOR

Rainone C.

showing 1 related works from this author

Emerging Therapies in Pheochromocytoma and Paraganglioma: Immune Checkpoint Inhibitors in the Starting Blocks

2021

Pheochromocytoma and paraganglioma are neuroendocrine neoplasms, originating in the adrenal medulla and in parasympathetic and sympathetic autonomic nervous system ganglia, respectively. They usually present as localized tumours curable with surgery. However, these tumours may exhibit heterogeneous clinical course, ranging from no/minimal progression to aggressive (progressive/metastatic) behavior. For this setting of patients, current therapies are unsatisfactory. Immune checkpoint inhibitors have shown outstanding results for several types of solid cancers. We therefore aimed to summarize and discuss available data on efficacy and safety of current FDA-approved immune checkpoint inhibitor…

atezolizumabatezolizumab; avelumab; cemiplimab; durvalumab; immune checkpoint inhibitors; ipilimumab; nivolumab; paraganglioma; pembrolizumab; pheochromocytomadurvalumablcsh:MedicineIpilimumabReviewImmune checkpoint inhibitorPembrolizumabBioinformaticsimmune checkpoint inhibitorsPheochromocytomaAvelumabparaganglioma03 medical and health sciences0302 clinical medicineParagangliomaAtezolizumabMedicineipilimumabAte-zolizumab030304 developmental biologynivolumab0303 health sciencesbusiness.industrylcsh:RGeneral Medicinemedicine.diseasepheochromocytomaClinical trial030220 oncology & carcinogenesisavelumabcemiplimabpembrolizumabNivolumabbusinessmedicine.drugJournal of Clinical Medicine
researchProduct